The expanding array of HIV broadly neutralizing antibodies
LE McCoy - Retrovirology, 2018 - Springer
A large array of broadly neutralizing antibodies (bnAbs) against HIV have been isolated and
described, particularly in the last decade. This continually expanding array of bnAbs has …
described, particularly in the last decade. This continually expanding array of bnAbs has …
HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design
CA Bricault, K Yusim, MS Seaman, H Yoon, J Theiler… - Cell host & …, 2019 - cell.com
Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …
[HTML][HTML] Non-neutralizing antibodies alter the course of HIV-1 infection in vivo
Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …
Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates
The development of an effective AIDS vaccine remains a challenge. Nucleoside-modified
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
mRNAs formulated in lipid nanoparticles (mRNA-LNP) have proved to be a potent mode of …
[HTML][HTML] An antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes
AS Dingens, D Arenz, H Weight, J Overbaugh… - Immunity, 2019 - cell.com
Anti-HIV broadly neutralizing antibodies (bnAbs) have revealed vaccine targets on the
virus's envelope (Env) protein and are themselves promising immunotherapies. The efficacy …
virus's envelope (Env) protein and are themselves promising immunotherapies. The efficacy …
Structure of the membrane proximal external region of HIV-1 envelope glycoprotein
The membrane-proximal external region (MPER) of the HIV-1 envelope glycoprotein (Env)
bears epitopes of broadly neutralizing antibodies (bnAbs) from infected individuals; it is thus …
bears epitopes of broadly neutralizing antibodies (bnAbs) from infected individuals; it is thus …
Characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein conformational states on infectious virus particles
ABSTRACT Human immunodeficiency virus (HIV-1) entry into cells involves triggering of the
viral envelope glycoprotein (Env) trimer ([gp120/gp41] 3) by the primary receptor, CD4, and …
viral envelope glycoprotein (Env) trimer ([gp120/gp41] 3) by the primary receptor, CD4, and …
Residues in the gp41 ectodomain regulate HIV-1 envelope glycoprotein conformational transitions induced by gp120-directed inhibitors
Interactions between the gp120 and gp41 subunits of the human immunodeficiency virus
type 1 (HIV-1) envelope glycoprotein (Env) trimer maintain the metastable unliganded form …
type 1 (HIV-1) envelope glycoprotein (Env) trimer maintain the metastable unliganded form …
Functional and highly cross-linkable HIV-1 envelope glycoproteins enriched in a pretriggered conformation
Binding to the receptor, CD4, drives the pretriggered,“closed”(state-1) conformation of the
human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer into more …
human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env) trimer into more …
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
The broadly neutralizing antibody (bnAb) VRC01 is being evaluated for its efficacy to
prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary …
prevent HIV-1 infection in the Antibody Mediated Prevention (AMP) trials. A secondary …